Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $12.29 USD
Change Today -0.09 / -0.73%
Volume 138.7K
SGMO On Other Exchanges
SGMO is not on other exchanges.
As of 10:48 AM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

sangamo biosciences inc (SGMO) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - $19.25
52 Week Low
10/13/14 - $9.39
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

sangamo biosciences inc (SGMO) Related Businessweek News

No Related Businessweek News Found

sangamo biosciences inc (SGMO) Details

Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for unmet medical needs in the United States. Its zinc finger DNA-binding proteins (ZFPs) could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways for genome editing and gene regulation; and ZFP transcription factors (ZFP TFs) proteins could be used to turn genes on or off. The company’s principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops CERE-110 that is in Phase II clinical trial for the treatment of Alzheimer’s disease. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, huntington’s disease, and hemoglobinopathies; and proprietary programs in the areas of lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including various immunodeficiencies, as well as central nervous system disorders and cancer immunotherapy. The company has collaboration and license agreements with Shire International GmbH and Biogen Idec Inc.; and strategic partnerships with Sigma-Aldrich Corporation, Dow AgroSciences, LLC, Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.

102 Employees
Last Reported Date: 02/25/15
Founded in 1995

sangamo biosciences inc (SGMO) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $650.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $405.0K
Chief Medical Officer and Vice President of T...
Total Annual Compensation: $440.0K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $425.0K
Executive Vice President of Research and Deve...
Total Annual Compensation: $460.0K
Compensation as of Fiscal Year 2014.

sangamo biosciences inc (SGMO) Key Developments

Sangamo Announces Encouraging Data from Lysosomal Storage Disorders Study

Sangamo BioSciences Inc. has announced encouraging data from its proprietary ZFP Therapeutic programs in disease models of lysosomal storage disorders, or LSDs. The data demonstrated durable expression of levels of functional enzyme sufficient to correct biomarkers of disease in mouse models of Hunter and Hurler syndromes, enabled by Sangamo's zinc finger nuclease (ZFN)-mediated genome editing technology. The LSD programs are part of Sangamo's In Vivo Protein Replacement Platform (IVPRP) portfolio of ZFP Therapeutics. The IVPRP uses ZFN-mediated genome editing to precisely insert disease-corrective genes into the albumin locus in the genome of liver cells. The correct version of the enzyme, which is defective in a genetic disease, is then made by the powerful machinery that normally drives albumin expression, leading to the production and secretion of the missing enzyme by the liver. A significant and sustained reduction in glycosaminoglycan (GAG) levels (a biomarker of lysosomal storage disorder progression) was observed in the urine and secondary tissue (liver, spleen, kidneys and lungs) in Hurler and Hunter mice 21 days post treatment with ZFNs. The accumulation of GAG oligosaccharides in the lysosomes of cells leads to dysfunction in several tissues throughout the body and is associated with symptoms of these LSDs. Production of the corrective enzyme was also shown to be durable through the twelve week study, consistent with earlier studies of the IVPRP for clotting factor, Factor IX, which demonstrated sustained production for over a year. The data also demonstrated that in models of Hurler and Hunter syndrome, high levels of human IDUA (hIDUA) and human IDS (hIDS) enzyme activity respectively, could be detected in the liver (site of expression) and plasma of treated animals. In addition, functional enzymes could be detected in secondary tissues such as the spleen, kidneys, and lungs, demonstrating that they had been taken up into these tissues from the circulation.

Sangamo Biosciences Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 01:30 PM

Sangamo Biosciences Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 01:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Edward O. Lanphier, Founder, Chief Executive Officer, President, Director and Member of Clinical Review Committee.

Sangamo BioSciences Provides Clinical Update on SB-728-T Program and Developments in Other ZFP Therapeutic Programs at American Society of Gene and Cell Therapy Annual Meeting

Sangamo BioSciences Inc. announced that clinical and preclinical data from several ZFP Therapeutic® programs and collaborations were presented in the first two days of the 18th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Two presentations featured clinical data from two trials of the company's ZFP Therapeutic, SB-728-T, which is being developed as a potential 'functional cure' for HIV/AIDS. The studies demonstrated the effect of SB-728-T treatment on both viral load control and HIV reservoir reduction in HIV-infected subjects. The presentation summarized further analysis of data from nine HIV-infected subjects, with sub-optimal T-cell levels and no detectable viral load on long-term ART, so-called immunologic non-responders (INRs) who were enrolled in an open-label Phase 1 clinical trial (SB-728-902 Cohorts 1-3). Clinicians observed long-term immune reconstitution of CD4 T-cells for the entire follow-up period (up to 3 years post treatment) at levels, and for periods, not seen in other HIV/T-cell trials, which was positively correlated beyond 12 months with the presence of an important T Memory Stem Cell CD4 subset (TSCM)  (r=0.7904, p=0.0279 at 3 years). The TSCM population had the high levels of ZFN modification and showed evidence of differentiation into other T-cell types.  Measures of circulating TSCM also correlated with the decay of the HIV reservoir which was observed in all subjects, with a statistically significant regression slope (R2 = 0.526, p = 0.042).  The data suggest that expansion (and potentially differentiation) of CCR5 modified TSCM may provide a long term source of protected T-cells resulting in a reduction in the HIV reservoir. In a second presentation demonstrating viral load (VL) control from three subjects treated in Cohort 3 of the company's SB-728-1101 clinical trial. After preconditioning with an optimal dose of Cytoxan (1.0 g/m2) to enhance modified cell engraftment, the subjects received a T-cell product containing both CCR5 modified CD4 and CD8 T-cells.  Six weeks post-treatment all three underwent a treatment interruption (TI) from their antiretroviral medication. Two of the three have demonstrated significant control of viral load, one to levels that are quantifiable but considered to render the subject non-infectious and one who demonstrated a one log drop from peak VL after a delayed onset of viremia. Both remain on TI. An additional five subjects will be accrued into this cohort to further evaluate the inclusion of ZFN-modified CD8 T-cells in the cell product. Two additional SB-728-T treated subjects continue to demonstrate VL control without ART, one in the 1101 trial (Cohort 5) for approximately nine months and one subject from the SB-728-902 Cohort 5 for more than 18 months.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGMO:US $12.32 USD -0.06

SGMO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bluebird Bio Inc $187.96 USD -3.02
Fibrocell Science Inc $4.91 USD +0.145
View Industry Companies

Industry Analysis


Industry Average

Valuation SGMO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.6x
Price/Book 4.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANGAMO BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at